{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 39,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/28",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.076,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Sources: Ou and Zhu Lung Cancer 2019; Kris et. al. JAMA 2014; Shaw and Engelman J Clin Onc 2013; Noé et. al. J Thor Onc 2019; Peters et. al. NEJM 2017; Shaw et. al. Lancet Onc 2017; Dagogo-Jack et. al. Clin Cancer Res 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5c11c8f-90bd-4c51-88ae-7fb787c77942",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.62,
        "w": 0.86,
        "x": 0.068,
        "y": 0.265
      },
      "kind": "table",
      "text": "Table showing Line of Therapy, Sub-population, Incidence, CNS Disease, and Standard of Care",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "716085f3-1cda-4ce2-9a40-56842121a493",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.076,
        "y": 0.185
      },
      "kind": "title",
      "text": "Emerging Resistance Mutations and Increasing CNS Involvement Limit Utility of Approved Therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79dbf15e-431e-49a1-9a8b-b6fead9874e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "ALK-Positive NSCLC Market Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "781d714b-a0f5-44bd-8ecf-a3cff3fb7336",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation",
      "slug": null,
      "matchId": "6b6eeb9c-ffad-4012-a864-331a2dc1c47a",
      "evidence": "The slide segments the ALK+ NSCLC market by line of therapy and specific genetic mutations.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}